AR049081A1 - Mediadores del transporte inverso de colesterol para el tratamiento de la hipercolesterolemia - Google Patents

Mediadores del transporte inverso de colesterol para el tratamiento de la hipercolesterolemia

Info

Publication number
AR049081A1
AR049081A1 ARP050102362A ARP050102362A AR049081A1 AR 049081 A1 AR049081 A1 AR 049081A1 AR P050102362 A ARP050102362 A AR P050102362A AR P050102362 A ARP050102362 A AR P050102362A AR 049081 A1 AR049081 A1 AR 049081A1
Authority
AR
Argentina
Prior art keywords
hypercholesterolemia
treatment
amino
mediators
amino acid
Prior art date
Application number
ARP050102362A
Other languages
English (en)
Inventor
Victor Charles Vassar
Igor Nikoulin
Jagadish C Sircar
Kashinatham Alisala
Original Assignee
Avanir Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avanir Pharmaceuticals filed Critical Avanir Pharmaceuticals
Publication of AR049081A1 publication Critical patent/AR049081A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic

Abstract

Composiciones adaptadas para mejorar el transporte inverso de colesterol en mamíferos. Las composiciones son adecuadas para una administracion oral y de utilidad en el tratamiento y/o la prevencion de hipercolesterolemia, aterosclerosis y enfermedades cardiovasculares asociadas. Reinvidicacion 1: Un mediador del transporte inverso de colesterol, que comprende la estructura de formula (1), donde, A, B y C pueden estar en cualquier orden, y donde A comprende un aminoácido o un análogo del mismo, que comprende un grupo ácido o un bioisostero del mismo; B comprende un aminoácido o un análogo del mismo, que comprende un grupo lipofílico; y C comprende un aminoácido o un análogo del mismo, que comprende un grupo básico o un bioisostero del mismo; donde al menos uno de los grupos alfa-amino o alfa-carboxilo han sido eliminados de sus respectivos aminoácidos amino o carboxilo terminales o análogos de los mismos.
ARP050102362A 2004-06-09 2005-06-09 Mediadores del transporte inverso de colesterol para el tratamiento de la hipercolesterolemia AR049081A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57822604P 2004-06-09 2004-06-09
US66736805P 2005-04-01 2005-04-01

Publications (1)

Publication Number Publication Date
AR049081A1 true AR049081A1 (es) 2006-06-21

Family

ID=34982204

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102362A AR049081A1 (es) 2004-06-09 2005-06-09 Mediadores del transporte inverso de colesterol para el tratamiento de la hipercolesterolemia

Country Status (15)

Country Link
US (1) US20070004644A1 (es)
EP (1) EP1753782A1 (es)
JP (1) JP2008509228A (es)
KR (1) KR20070029198A (es)
AR (1) AR049081A1 (es)
AU (1) AU2005255013A1 (es)
BR (1) BRPI0511945A (es)
CA (1) CA2568543A1 (es)
IL (1) IL179302A0 (es)
MX (1) MXJL06000068A (es)
NO (1) NO20070140L (es)
PE (1) PE20060082A1 (es)
TW (1) TW200603795A (es)
UY (1) UY28952A1 (es)
WO (1) WO2005123770A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2410392C2 (ru) * 2009-02-16 2011-01-27 Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН Дипептидные миметики нейротрофинов ngf и bdnf

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773946A (en) * 1969-09-02 1973-11-20 Parke Davis & Co Triglyceride-lowering compositions and methods
US3930024A (en) * 1969-09-02 1975-12-30 Parke Davis & Co Pharmaceutical compositions and methods
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
IL64542A0 (en) * 1981-12-15 1982-03-31 Yissum Res Dev Co Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
JPS60136512A (ja) * 1983-12-26 1985-07-20 Eisai Co Ltd 脂質代謝改善剤
US4643988A (en) * 1984-05-15 1987-02-17 Research Corporation Amphipathic peptides
DE3423166A1 (de) * 1984-06-22 1986-01-02 Epis S.A., Zug Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
AU8334298A (en) * 1997-07-15 1999-02-10 Novo Nordisk A/S Nociceptin analogues
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
ATE384035T1 (de) * 1999-04-01 2008-02-15 Esperion Therapeutics Inc Ether-verbindungen, zusammensetzungen und ihre verwendung
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
FR2820435B1 (fr) * 2001-02-05 2004-02-27 Genfit S A Procedes d'identification de composes modulant le transport inverse du cholesterol
CA2522758A1 (en) * 2003-04-22 2004-11-04 Avanir Pharmaceuticals Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
US20060009487A1 (en) * 2004-06-09 2006-01-12 Sircar Jagadish C Heterocyclic derivatives for treatment of hyperlipidemia and related diseases
CN1964955A (zh) * 2004-06-09 2007-05-16 阿文尼尔药品公司 治疗高胆固醇血症及相关疾病的小分子

Also Published As

Publication number Publication date
MXJL06000068A (es) 2007-04-10
AU2005255013A1 (en) 2005-12-29
BRPI0511945A (pt) 2008-01-29
EP1753782A1 (en) 2007-02-21
UY28952A1 (es) 2006-01-31
US20070004644A1 (en) 2007-01-04
KR20070029198A (ko) 2007-03-13
PE20060082A1 (es) 2006-02-09
IL179302A0 (en) 2007-03-08
WO2005123770A1 (en) 2005-12-29
TW200603795A (en) 2006-02-01
NO20070140L (no) 2007-03-07
CA2568543A1 (en) 2005-12-29
JP2008509228A (ja) 2008-03-27

Similar Documents

Publication Publication Date Title
AR049216A1 (es) Derivados heterociclicos como mediadores del transporte inverso del colesterol para el tratamiento de hiperlipidemia y enfermedades cardiovasculares relacionadas
ECSP21056710A (es) Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar
CR20220315A (es) Compuestos de benzoti(di)azepina y su uso como moduladores del ácido biliar
UY30485A1 (es) Uso antiviral de un tensioactivo cationico
CL2022001453A1 (es) Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar
ATE216230T1 (de) Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen
AR076349A1 (es) Peptido auxiliar del antigeno del cancer
JP2017509634A5 (es)
AR022224A1 (es) Gen de la desaturasa humana y usos del mismo
UA102477C2 (en) Capsule composition
RU2008103281A (ru) Способы и композиции для профилактики и лечения воспалительного заболевания
CR9177A (es) Conjugados de factor de crecimiento-1 similar a insulina y polietilenglicol
CO2023016072A2 (es) Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
ATE413865T1 (de) Zusammensetzungen mit alphahydroxy-säureester zur wirkstofffreisetzung und anwendungsverfahren dafür
CO5160323A1 (es) Formulaciones farmaceuticas mejoradas vir en combinacion con otros inhibidores de proteasa vih
BR0306655A (pt) Genes elongase e usos dos mesmos
NO20084478L (no) Konjugerte lipidderivater
AR082644A1 (es) Tetranectina-apolipoproteina a-i, particulas lipidicas que la contiene y utilizacion de la misma relacionado con el metabolismo de los lipidos y las enfermedades cardiovasculares
BRPI0606445A2 (pt) inibidores de hipersecreÇço de mucina e mÉtodos de uso
PE20050923A1 (es) Composicion solida que comprende un sensibilizador de insulina, un secretagogo de insulina y un ester de acidos grasos
AR049081A1 (es) Mediadores del transporte inverso de colesterol para el tratamiento de la hipercolesterolemia
UY28282A1 (es) Mediadores peptidicos del trasporte inverso de colesterol para el tratamiento de hipercolesterolemia
AR049217A1 (es) Pequenas moleculas para el tratamiento de hipercolesterolemia y enfermedades relacionadas
PE20091235A1 (es) Composiciones que comprenden acido asiatico y/o acido madecasico
PE20212373A1 (es) Composiciones de acidos grasos poliinsaturados enriquecidos con dha

Legal Events

Date Code Title Description
FB Suspension of granting procedure